Cargando…
1740. Healthcare Providers’ Preferences for Pediatric Pneumococcal Vaccination Recommendations in the United States
BACKGROUND: A 20-valent pneumococcal conjugate vaccine (PCV20) was recently licensed for use in children by the United States (US) Food and Drug Administration. PCV20 includes 5 and 7 more serotypes than the 15- (PCV15) and 13-valent (PCV13) vaccines, respectively. This study assessed healthcare pro...
Autores principales: | Vietri, Jeffrey T, Myers, Kelley H, Huang, Liping, Snow, Vincenza, Hauber, Brett, Arguedas, Adriano, Cane, Alejandro D, Tort, Maria J, Pierce, Anna, Poulos, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679108/ http://dx.doi.org/10.1093/ofid/ofad500.1571 |
Ejemplares similares
-
Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers
por: Sacco, Patricia, et al.
Publicado: (2019) -
06. United States Healthcare Provider Preferences for Adult Pneumococcal Vaccine Recommendations
por: Vietri, Jeffrey, et al.
Publicado: (2021) -
1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023) -
1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
por: Rozenbaum, Mark, et al.
Publicado: (2023) -
576. Burden of Pneumococcal Disease Due to Serotypes Covered by the 13-Valent and New Higher-Valent Pneumococcal Conjugate Vaccines in All Children and Children at Risk in the United States
por: Huang, Liping, et al.
Publicado: (2022)